Course InformationTherapautic Area: Pulmonolgy
Format(s): Post Conference Review and Analysis
Credit(s): 1.0 AMA PRA Category 1 Credit™; 1.0 CNE contact hour
Activity Dates: September 7, 2018 - September 6, 2019
This CME/CNE activity will review recent advances in Patients with Idiopathic Pulmonary Fibrosis (IPF) as presented at the American Thoracic Society (ATS) 2018 Conference in San Diego, California. The three expert faculty will analyze evidence based data on the current science and emerging therapeutics for the treatment of IPF. The faculty will also discuss how to collaborate with the interprofessional team to apply optimal management strategies for improved outcomes in patients with IPF. Upon completion of this activity, learners will gain knowledge on how to implement emerging therapeutics of idiopathic pulmonary fibrosis to treat patients and ultimately improve patient outcomes.
Pulmonologists, internists, nurse practitioners, and other healthcare professionals involved in the management of patients with IPF
1. Analyze evidence-based data on the current science and emerging therapeutics for the treatment of IPF, as presented at ATS 2018
2. Collaborate with the interprofessional team to apply optimal management strategies for improved outcomes in patients with IPF
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
|Faculty||Relationship Identified With:|
|Gerard J. Criner, MD, FACP, FACCP||Nothing to disclose.|
|Michelle Vega-Olivo, CRNP, MSN, FNP-BC||Speaker’s Bureau: Circassia Therapeutics; Genentech, Inc|
|Fernando J. Martinez, MD||Consultant/Advisor: AstraZeneca; BioScale/ProTerrix; Boehringer Ingelheim Pharmaceuticals, Inc; Bridge Biotherapeutics; Chiesi USA, Inc.; Genentech, Inc; GlaxoSmithKline plc; Sunovion; Teva Pharmeceuticals Industries Ltd.; The Zambon GroupGrant/Research Support: AstraZeneca; Bayer AG; Biogen; Boehringer Ingelheim Pharmaceuticals, Inc; Gilead Sciences, Inc.; GlaxoSmithKline plc; Nitto Pharmaceuticls; Patar Phara; ProMedior; Prometic Life Sciences; Veracyte|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD and Emma Boring hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour.
This activity has been supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Boehringer Ingelheim Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions.
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
8. 60 minutes of participation = 1 CNE contact hour
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact email@example.com.